Cromedil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cromedil

Quick Facts: Cromedil (Sodium Cromoglycate)

Property Description
Active ingredient Sodium Cromoglycate (Disodium Cromoglycate)
Form Nasal spray, Ophthalmic solution, Inhalation solution
Pharmacological class Mast Cell Stabilizer
Common use Prophylactic (preventive) allergy management
Origin Synthetic compound derived from a natural chromone

Sodium Cromoglycate: A Prophylactic Mast Cell Stabilizer

Cromedil is a synthetic anti-allergic medication intended exclusively for prevention, whose active ingredient is Sodium Cromoglycate (Disodium Cromoglycate). This compound is officially classified as a Mast Cell Stabilizer. This designation means its action differs from traditional treatments, as it operates by stabilizing specific immune cells before an allergic reaction can fully develop. The drug is utilized in a prophylactic context, contrasting sharply with acute treatments intended for immediate symptom relief. This mechanism works by inhibiting the cellular processes that lead to inflammation.

Forms and Purpose in Allergy Maintenance

The primary therapeutic purpose of the medication is its role in maintenance therapy for managing localized allergic responses, preventing the onset of symptoms such as irritation in the eyes or nose. The medication is supplied as a single-ingredient product in specialized forms intended for topical application onto mucous membranes. These commonly include an ophthalmic solution for eye allergies and an aqueous solution for nasal spray administration. Clinically, the drug is recognized for its ability to prevent the release of histamine and other inflammatory mediators from mast cells. This means the medicine helps reduce irritation and discomfort by stopping the allergic reaction at its source. This function is why the medication is often used consistently by patients anticipating exposure to seasonal allergens to maintain a protective barrier.

What side effects are possible with Cromedil?

Possible side effects and safety information

The adverse reactions and general safety characteristics associated with Cromedil (Sodium Cromoglycate) are based on official regulatory documentation, with effects often being localized due to the medication’s prophylactic, topical administration. Safety classifications may vary by region; the following terminology is consistent with official regulatory prescribing information.

Common Adverse Reactions and Organ Systems

The most frequently reported adverse reactions are local effects experienced immediately upon administration and are classified as common or very common.

System-Organ Class Common Adverse Reactions
Respiratory, Thoracic Nasal irritation, sneezing, throat irritation, coughing.
Gastrointestinal Diarrhea, abdominal pain, nausea (primarily oral form).
Nervous System Headache.
Eye Disorders Transient stinging or burning upon application.

Serious Adverse Reactions and Safety Constraints

Official labeling documents the potential for less common, yet clinically significant, adverse events. These documented serious adverse reactions include the potential for anaphylaxis and angioedema (severe allergic reactions), and severe or paradoxical bronchospasm, particularly following inhalation use.

The medication is contraindicated in any individual with a known history of hypersensitivity to Sodium Cromoglycate. Furthermore, official safety notes advise caution and consideration for use in patients with significant hepatic or renal impairment, as the drug's clearance may be affected by reduced function. The regulatory designation confirms the medicine is not intended for the treatment of acute symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cromedil (Sodium Cromoglycate) overdose consistently reports a low risk of acute toxicity. This is primarily attributed to the drug's very poor systemic absorption across all administration routes, including nasal spray, ophthalmic solution, and oral solution.

Documented Overdose Profile

Government prescribing information states clearly that no specific clinical syndrome is documented as being associated with an acute overdosage of this medicine. Due to this finding and the low systemic exposure, regulatory documents do not specify any severe, systemic, or life-threatening manifestations resulting from overexposure.

Mandated Response and Supervision

The low-risk classification dictates the required action for a known or suspected overdosage. Regulatory authorities mandate that the primary response should be medical observation or medicinal supervision. This procedure is generally considered the only necessary intervention, and specific therapeutic or procedural steps, beyond symptomatic support, are not detailed in official overdose sections. Individuals concerned about overdosage should seek professional guidance regarding this required monitoring.

Population-Specific Note

A note is included for patients with impaired renal or hepatic function. Given that the drug is cleared from the body via the bile and kidneys, any potential for altered systemic exposure must be given special consideration by supervisory staff during the period of medical observation following a suspected overdosage.

Therapeutic Uses of Cromedil

Quick Facts: Uses of Cromedil

  • Helps manage chronic bronchial asthma.
  • Assists in the prevention of acute bronchospasm caused by triggers like exercise or cold air.
  • Supports the management of mastocytosis symptoms, including diarrhea, abdominal pain, and nausea.
  • Used to address allergic eye conditions such as vernal keratoconjunctivitis.

Cromedil (cromolyn sodium) is a medication utilized in the management of several conditions, serving primarily as a prophylactic agent. It is generally intended for patients whose symptoms are frequent enough to require a continuous program of medication. Cromedil is approved for the management of bronchial asthma, where it helps support a reduction in the severity and occurrence of asthma symptoms when taken regularly. It is not used to treat acute asthma attacks that have already begun.

Furthermore, the medication is indicated to help prevent the occurrence of acute bronchospasm that may follow exposure to specific factors, such as exercise or certain environmental pollutants.

In oral solution form, Cromedil is used in the management of patients with mastocytosis, a condition associated with the buildup of mast cells. Use of this product has been associated with improvement in various systemic and cutaneous manifestations of mastocytosis, including flushing, headaches, abdominal pain, vomiting, and itching in some patients. Additionally, the ophthalmic solution is used to address the symptoms of certain allergic eye conditions.

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility profile for this medicine (cromolyn sodium oral solution) is defined by a set of formal exclusions and restrictions documented in official government regulatory labeling.

Contraindications (Must NOT Use)

  • Patients who have demonstrated hypersensitivity or an allergic reaction to cromolyn sodium or any other component of the product are formally contraindicated from use.

Restricted or Conditional Use

  • Pediatric Patients: Use in children younger than two years of age is generally not recommended and should only be considered for severe conditions where the potential benefits are clearly determined to outweigh the risks.
  • Kidney or Liver Impairment: Patients with reduced renal or hepatic function require special consideration, and the recommended dosage must be decreased due to the drug’s excretion routes.
  • Pregnancy: The medicine is classified as Pregnancy Category B, meaning animal studies have not shown harm, but human data are lacking. Use during pregnancy is conditional and only advised if clearly needed.
  • Breastfeeding: It is unknown if the drug is excreted into human milk. Caution is formally recommended when the medicine is administered to a nursing woman.

Age-Group Eligibility

Population Regulatory Status
Children under 2 years Not recommended; use reserved for severe disease.
Adults and Children 2 years and older Generally permitted for use.
Older Adults (Geriatric) Use should be cautious, often starting at a lower dose, due to the higher probability of decreased organ function.

What should I know about interactions with other medicines?

Cromedil Interactions with Other Medicines and Products

Cromedil (Sodium Cromoglycate) has an official interaction profile characterized by limited systemic absorption, meaning regulatory agencies have documented no interactions involving the CYP enzyme system or drug transporters.

Documented Interactions and Restrictions

Interacting Substance Official Description of Interaction Pattern
Oxymetazoline May decrease the absorption of Cromedil.
Methacholine May decrease the effectiveness of Methacholine when it is used for diagnostic purposes.
Isoproterenol Potential for increased risk when combined; this is based on non-clinical high-dose animal studies.

Regulatory Constraints and Cautions

Regulatory documentation emphasizes specific administration constraints for the oral solution and population-specific cautions due to drug clearance:

  • Food and Beverages: The oral concentrate must be administered on an empty stomach and is officially restricted from being mixed with fruit juice, milk, or food to ensure proper function.
  • Timing: The oral solution must be taken 30 minutes prior to meals and at bedtime.
  • Altered Clearance: Patients with impaired renal or hepatic function may require adjustment of the regimen due to the drug's combined renal and biliary excretion, which could affect overall drug exposure.

Mechanism of Action

The action of Sodium Cromoglycate is focused on two distinct physiological pathways, achieving its effect by preventing cellular activation rather than reversing it. The molecule primarily acts as a mast cell stabilizer, engaging mechanisms that interfere with the integrity of the cell membrane. This action functionally blocks the essential influx of calcium ions ( Ca^2+), the biochemical signal required for the cell to undergo degranulation and release its contents. By suppressing this Ca^2+-dependent cascade, the drug achieves an upstream inhibition of mediator secretion, halting the release of active inflammatory agents like histamine and leukotrienes into the surrounding tissue. This modification of early molecular steps prevents the initiation of the inflammatory sequence, maintaining a state of physiological stability in targeted mucosal areas. Additionally, evidence suggests the drug acts as an agonist at the GPR35 receptor on sensory C fibers, modulating local neuro-immune signaling. Crucially, the mechanism is strictly prophylactic and cannot reverse established tissue reactions; its action is constrained to preventing the initial cellular event and does not counteract mediators that have already been released.

Dosage and Administration Information

How Cromedil (Sodium Cromoglycate) is Used

Cromedil is utilized exclusively as a prophylactic agent (preventive medication), which mandates continuous, regular administration to prevent symptoms, rather than for immediate relief of acute episodes. The efficacy of the medicine depends on adherence to the established schedule over a sustained duration, as the full effect may not be apparent until several weeks into the regimen.

Administration Routes and Dosing Patterns

The medication is administered via routes corresponding to the targeted site of action:

  • Oral Solution: Used for systemic conditions, requiring ingestion. The oral concentrate must be diluted with a glass of water and taken 30 minutes before meals and at bedtime. This form is explicitly not intended for inhalation or injection.
  • Inhalation Solution/Aerosol: Administered by oral inhalation for lung conditions, requiring a power-driven nebulizer for the solution form.
  • Topical Forms: Used locally as an ophthalmic solution (eye drops) or a nasal spray.

Standard Dosing Frequency and Timing

For most systemic and inhaled maintenance therapies, the medication is administered four times daily (QID) at regular, equally spaced intervals. Topical forms are typically dosed three to six times daily. When the inhaled form is used to prevent acute bronchospasm from a specific trigger, such as exercise, the dose is administered preemptively, 10 to 60 minutes prior to the exposure.

Population and Dosage Adjustments

Specific guidelines exist for various populations. For pediatric patients (children 2 to 12 years) requiring the oral solution, a lower starting dose (e.g., 100 mg QID) is utilized. Furthermore, a decrease in the oral dose should be considered in patients with reduced kidney or liver function. Once symptoms are controlled, the dose may be gradually reduced to the minimum necessary level required for maintenance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cromedil

Evidence for use in Chronic Kidney Disease (CKD)

Research exploring Cromedil for Chronic Kidney Disease (CKD) has primarily relied on large randomized controlled trials (RCTs) focusing on adults with varying stages of kidney function decline. These studies monitored outcomes related to the kidney, such as changes in the estimated glomerular filtration rate (eGFR), and levels of albuminuria. Cardiovascular outcomes, including the incidence of major heart events and hospitalizations for heart failure, were also tracked over defined time intervals. Studies report measurements of eGFR over several years, and data describe patterns related to measurements of albuminuria levels in the observed populations. Limited information is available for long-term outcomes in the most severe stages of kidney function decline.


Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Cromedil was evaluated in numerous RCTs and long-term extension studies in adults with Type 2 Diabetes. The research examined changes in glycemic control indicators, such as HbA1c and fasting blood sugar levels. Studies also monitored changes in body weight and the frequency of hypoglycemic events, as well as measurements of long-term cardiovascular and kidney-related events. The trials reported measurements of HbA1c levels and body weight measurements during the study period across the study groups. Findings describe patterns observed in the incidence of certain cardiovascular events in the tested populations. This research contributes to the broader evidence landscape.


Evidence for use in Heart Failure (HF)

Research has explored the use of Cromedil in patients with heart failure (HF), specifically those with reduced ejection fraction (HFrEF) and, more recently, those with preserved ejection fraction (HFpEF). Studies monitored outcomes describing episodic or acute changes, focusing on the incidence of cardiovascular death and hospitalizations related to worsening heart failure. The large-scale research reports measurements of the incidence of heart failure-related hospitalizations and overall survival measurements over the study duration. Data for certain groups, particularly those with HFpEF, are still emerging, and comparative evidence is lacking in specific populations.


What is still uncertain about Cromedil research

Despite the available evidence, certain areas remain where research is ongoing, and certainty remains low. The results apply only to the specific populations studied, and findings describe group patterns, not personal outcomes, meaning research does not determine whether an individual will respond similarly. Key limitations include the fact that comparative evidence is lacking for certain other studied compounds, and subgroup findings are uncertain for very specific combinations of comorbidities.

Key Studies & References

  1. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Cromedil (FAQ)

Q: What happens if I forget a dose of Cromedil?

Official product information advises taking a missed dose as soon as it is recalled. If it is nearly time for the next scheduled dose, skipping the missed dose and continuing with the regular schedule is described. Regulatory guidance states that double doses must be avoided.

Q: Is it normal to feel tired after starting Cromedil?

Tiredness or fatigue is not typically listed as a common or frequently reported adverse reaction in the official regulatory documents for the various forms of the medicine. The most commonly reported effects are generally localized or related to the digestive system, such as headache or diarrhea.

Q: Does Cromedil cause any mood changes?

Some regulatory adverse effect profiles have documented effects such as irritability and behavior changes, although the frequency is generally not defined. In certain documented instances, psychosis has also been mentioned.

Q: Is there a generic version of Cromedil available?

Yes, official regulatory agencies, such as the FDA, have approved Abbreviated New Drug Applications (ANDA) for generic equivalents of Cromedil. Regulatory findings confirm these generic versions are considered bioequivalent and therapeutically equivalent to the brand-name product.

Q: How long does Cromedil stay in your system?

Pharmacokinetic data from official sources indicates that the medicine has a relatively short elimination half-life. This half-life is typically reported to be in the range of 80 to 90 minutes.

Q: Does alcohol interact negatively with Cromedil?

Regulatory information on drug interactions does not typically list alcohol as a direct contraindication or documented negative interaction with Cromedil. Official warnings focus primarily on restrictions related to mixing the oral form with certain beverages like fruit juice or milk.

Q: Is Cromedil a controlled substance?

The official regulatory classification for Cromedil confirms that it is not considered a controlled substance.

Q: Is Cromedil safe to use before driving or operating machinery?

Official adverse reaction lists have included reports of lightheadedness. Regulatory guidance indicates that caution is necessary when driving or operating machinery if reactions such as these are experienced.

Q: What is the duration of the effect of one dose of Cromedil?

Official pharmacological data indicates that the preventive effect of a single dose of the medicine lasts for approximately 6 hours. This duration aligns with the typical administration schedule described to help maintain continuous, prophylactic protection.

Q: Does Cromedil cause rebound effects if stopped suddenly?

Regulatory cautions note that the original symptoms may reoccur or worsen when the medicine is tapered or stopped. Caution is indicated for the inhaled formulation due to the potential for rebound bronchospasm, which is a worsening of breathing symptoms.

Q: Is Cromedil available in different strengths?

Yes, official documentation confirms that Cromedil is supplied in various strengths across its different forms. Examples include the oral concentrate at 100 mg/5 mL and the nebulizer solution at 20 mg/2 mL.

Q: Does Cromedil cause sleepiness?

Official regulatory lists of side effects do not typically include sleepiness or drowsiness as a common reaction. Regulatory reviews note that the medication is generally considered non-sedating.

Q: Does Cromedil affect blood pressure or heart rate?

Some adverse reaction lists have included rare cardiovascular effects such as palpitations or premature ventricular contractions. Official regulatory documents indicate that caution is considered for use in patients with a history of cardiac arrhythmia (irregular heartbeat).

Q: What should I do if a side effect of Cromedil is bothersome?

Official patient safety guidance universally advises that any side effect that is bothersome, persistent, or causes concern is an appropriate reason to seek consultation from a healthcare professional, such as a doctor or pharmacist.

Q: Is Cromedil only available with a prescription?

The regulatory classification of Cromedil varies depending on the specific formulation. Certain forms, such as the nasal spray, are officially available over-the-counter (OTC), while other forms, like the oral solution, typically require a prescription.

Q: What is the difference between the brand name and generic versions of Cromedil?

Official regulatory processes, such as the FDA's approval of generic drugs, require them to be bioequivalent and therapeutically equivalent to the brand-name product. This regulatory finding indicates that generic versions are expected to provide the same clinical benefit.

Q: How is Cromedil different from other similar treatments?

Official regulatory descriptions emphasize that Cromedil is a mast cell stabilizer and is used exclusively as a prophylactic (preventive) agent. This mechanism distinguishes its function from other drug classes, such as rescue medications intended for immediate relief.

Q: How quickly does Cromedil start working?

As a prophylactic medicine, Cromedil has a gradual onset of effect. Official labeling notes that the initial clinical response for the oral form is typically observed within 2 to 6 weeks, and continuous use is described as necessary to achieve the full preventive benefit.

Q: Are there any common over-the-counter medicines that interact with Cromedil?

Due to the medicine's limited systemic absorption, major drug interactions are generally not expected. However, regulatory patient safety guidance consistently advises that information about all prescription and over-the-counter medicines being used is provided to a healthcare professional.

Q: Why do doctors prescribe Cromedil instead of something else?

Regulatory reviews describe that the medicine has a safety profile that can make it suitable for initial therapy or for sensitive populations who require a prophylactic agent. This non-systemic mechanism supports its distinct therapeutic use, particularly for mild or maintenance cases.

Q: Can Cromedil be crushed or chewed?

Official administration instructions for the oral solution specify that the liquid contents must be diluted with water and consumed immediately. Regulatory guidance indicates that the physical form of any medication should not be altered unless explicitly permitted by official labeling, as separate instructions exist for the inhalation and topical forms.

Q: Does Cromedil interact with vitamins or herbal supplements?

Official regulatory patient safety guidance indicates that information about all products being used, including any prescription or over-the-counter medicines, vitamins, minerals, herbal products, and other supplements, is provided to a healthcare professional.

Q: Why is Cromedil prescribed for more than one condition?

The core reason relates to its mechanism of action: Cromedil functions as a mast cell stabilizer. This process prevents the release of various inflammatory mediators, providing a pharmacological basis for its use across multiple conditions that involve this type of inflammation.

How should Cromedil be stored and disposed of?

How to Store and Dispose of Cromedil

The storage and disposal of Cromedil (Cromolyn Sodium) must strictly adhere to the conditions mandated by official regulatory labeling to ensure product integrity and safety.

Required Storage Conditions

Cromedil must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must not be frozen and must be kept in its original container, tightly closed, to provide protection from light and moisture. To prevent accidental ingestion, the medication must always be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Cromedil must be disposed of in accordance with local regulations. Disposal should utilize established drug take-back programs when available. If take-back options are unavailable, the medicine should be mixed with an unappealing substance, sealed in a container, and placed in the household trash. The product should not be released into the environment or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cromedil found in:

A-Z Index: